Daesung Microbiological Labs대성미생물
036480 · KOSDAQ · ₩036480 · 대성미생물
- Market cap
- ₩21B
- Enterprise value
- ₩28B
- P/E
- 26.6×
- P/B
- 0.6×
- Dividend yield
- 1.4%
- ROE
- 2.3%
- Net margin
- 3.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−49.7% from the high
₩5,400Today: ₩5,510 – ₩5,700₩10,960
Returns
- 1W−6.0%
- 1M−8.8%
- 3M−15.5%
- 6M−28.3%
- YTD−24.5%
- 1Y−25.9%
- Volume today
- 5,804
- 1.2× the 20-day average
- Traded today
- ₩32M
- Listed shares
- 3,800,000
- EPS (12 months)
- ₩207
- Earnings yield 3.8%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 47 of 100 (50 is a normal day for this stock).
- MomentumWeak-10.4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Daesung Microbiological Labs stock overview
Daesung Microbiological Labs (대성미생물, KRX: 036480) is listed on KOSDAQ, in the Biotech & Pharma sector. The company, founded in 1966, is a Korean specialty maker of veterinary medicines for livestock, offering more than 150 products including vaccines (notably a foot-and-mouth disease vaccine), antibiotics, antiparasitics, nutritional supplements and disinfectants. Its shares closed at ₩5,510 on Oct 26, 2026, down 2.30% on the day, giving it a market value of ₩21B.
Key facts
- Market cap
- ₩21B
- Sector
- Biotech & Pharma
- Latest price change
- −2.30%
- As of
- Oct 26, 2026
- Main business
- The company, founded in 1966, is a Korean specialty maker of veterinary medicines for livestock, offering more than 150 products including vaccines (notably a foot-and-mouth disease vaccine), antibiotics, antiparasitics, nutritional supplements and disinfectants.
Quick answers about Daesung Microbiological Labs
- What does Daesung Microbiological Labs do?
- The company, founded in 1966, is a Korean specialty maker of veterinary medicines for livestock, offering more than 150 products including vaccines (notably a foot-and-mouth disease vaccine), antibiotics, antiparasitics, nutritional supplements and disinfectants. It sells domestically through about 200 distributors and via government procurement to public agencies nationwide, and exports to eight countries, mainly Pakistan, Vietnam and Russia.
- What is the market cap of Daesung Microbiological Labs?
- The market capitalisation of Daesung Microbiological Labs was ₩21B at the close on Oct 26, 2026.
- Who are the largest shareholders of Daesung Microbiological Labs?
- According to the latest official filings, the largest reported holders are Insilico (39.60%, as of Jun 4, 2026); Choi Seung-hun (1.00%, as of Jun 1, 2026).
- When is the next earnings report from Daesung Microbiological Labs?
- Korean companies rarely announce results dates in advance. Based on when Daesung Microbiological Labs filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 14, 2026.
Company profile
The company, founded in 1966, is a Korean specialty maker of veterinary medicines for livestock, offering more than 150 products including vaccines (notably a foot-and-mouth disease vaccine), antibiotics, antiparasitics, nutritional supplements and disinfectants. It sells domestically through about 200 distributors and via government procurement to public agencies nationwide, and exports to eight countries, mainly Pakistan, Vietnam and Russia.
Written by AI from the company's latest annual report.
- Korean name
- 대성미생물
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 최승훈
- Founded
- Feb 1966
- Listed
- Apr 2000
- Listed shares
- 3,800,000
- Fiscal year ends
- Month 12
- Website
- www.dsmbio.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Amended: Major sales or supply contractSep 30, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJun 4, 2026
- Insider shareholding reportJun 2, 2026
- Insider shareholding reportJun 1, 2026
Titles in Korean until English translations are added.
Also known as: Daesung Microbiological Labs / 대성미생물 / 036480 / KRX:036480
Source: KRX statistical information